Paper Details

  1. Home
  2. Paper Details

Treatment of multiple myeloma: a randomized study of three different regimens.

Author: AmadoriS, BoccadoroM, CantonettiM, CenturioniR, DammaccoF, FranchiA, PapaG, PileriA, TribaltoM, VaccaA

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 133 patients with multiple myeloma compared three chemotherapy regimens: melphalan plus prednisone (MP), vincristine, melphalan, cyclophosphamide, and prednisone (VMCP), and a sequential regimen of Peptichemio, cyclophosphamide, and BCNU. MP and VMCP resulted in higher response rates (35% and 46%, respectively) compared to the sequential regimen (3%). However, no significant differences were observed in overall survival between the groups. The duration of remission was similar between the MP and VMCP groups, with a median of 16 months. The study suggests that adding vincristine to chemotherapy may not improve survival and that longer induction treatment (12 cycles) may be needed to better compare the effectiveness of MP and VMCP regimens.
Paper Details　
Original Abstract of the Article :
The results of an Italian multicentric trial for treatment of symptomatic Multiple Myeloma (MM) are reported. One hundred and thirty-three previously untreated patients were singled out at random for three different chemotherapy schedules: Melphalan plus Prednisone (M.P.) X 6 monthly cycles; Vincris...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0145-2126(85)90075-x

データ提供：米国国立医学図書館（NLM）

Multiple Myeloma Treatment: A Randomized Study of Three Regimens

Multiple myeloma, a type of cancer affecting plasma cells in the bone marrow, requires aggressive treatment strategies. This research investigates the efficacy of three different chemotherapy regimens in the treatment of symptomatic multiple myeloma. The study, conducted in Italy, randomly assigned 133 previously untreated patients to receive one of three chemotherapy regimens: Melphalan plus Prednisone (MP), Vincristine plus Melphalan plus Cyclophosphamide plus Prednisone (VMCP), or a sequential regimen of Peptichemio, Cyclophosphamide, and BCNU.

Chemotherapy Regimens for Multiple Myeloma: A Comparison of Efficacy

The study found that the VMCP regimen resulted in a higher response rate than the MP regimen, but there was no significant difference in survival outcomes between the three treatment groups. It's like exploring different paths through a desert, each leading to the same destination but offering different challenges and rewards along the way. The study highlights the importance of individual patient factors and the need for personalized treatment approaches in multiple myeloma.

Navigating the Landscape of Multiple Myeloma Treatment

The research underscores the complexities of treating multiple myeloma. It's a reminder that the journey through the desert of cancer treatment is often long and challenging. The study emphasizes the need for continued research to identify more effective and personalized treatment strategies for multiple myeloma, offering hope for individuals battling this disease.

Dr.Camel's Conclusion

This study delves into the complex world of multiple myeloma treatment, a journey through the desert of cancer. The study highlights the importance of finding the right path for each individual patient, considering the various treatment options and their potential benefits and challenges. The findings underscore the need for continued research and development of more effective and personalized therapies, ultimately offering hope for a brighter future for individuals battling multiple myeloma.

Date :
  1. Date Completed 1985-11-15
  2. Date Revised 2019-08-24
Further Info :

Pubmed ID

3900591

DOI: Digital Object Identifier

10.1016/0145-2126(85)90075-x

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.